Alimera Sciences (ALIM) Cut to “Hold” at Zacks Investment Research

Zacks Investment Research downgraded shares of Alimera Sciences (NASDAQ:ALIM) from a buy rating to a hold rating in a report issued on Friday.

According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “

How to Become a New Pot Stock Millionaire

A number of other research firms have also recently commented on ALIM. HC Wainwright reaffirmed a buy rating and issued a $5.00 price target on shares of Alimera Sciences in a report on Monday, January 22nd. ValuEngine raised shares of Alimera Sciences from a strong sell rating to a sell rating in a report on Monday, November 27th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Alimera Sciences presently has a consensus rating of Hold and a consensus target price of $3.31.

Shares of Alimera Sciences (NASDAQ ALIM) opened at $1.10 on Friday. The company has a debt-to-equity ratio of -0.64, a quick ratio of 3.91 and a current ratio of 4.07. Alimera Sciences has a 1-year low of $1.03 and a 1-year high of $1.70.

Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.07). The company had revenue of $9.14 million for the quarter, compared to the consensus estimate of $9.60 million. equities analysts forecast that Alimera Sciences will post -0.06 EPS for the current year.

In other Alimera Sciences news, CEO C. Daniel Myers sold 52,900 shares of the business’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total transaction of $65,067.00. Following the sale, the chief executive officer now owns 154,411 shares of the company’s stock, valued at approximately $189,925.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Philip Ashman sold 25,500 shares of the business’s stock in a transaction on Friday, January 19th. The shares were sold at an average price of $1.20, for a total transaction of $30,600.00. Following the sale, the senior vice president now directly owns 12,750 shares in the company, valued at approximately $15,300. The disclosure for this sale can be found here. Insiders have sold a total of 184,704 shares of company stock worth $224,432 in the last three months. Insiders own 14.70% of the company’s stock.

A hedge fund recently raised its stake in Alimera Sciences stock. Stonepine Capital Management LLC raised its holdings in shares of Alimera Sciences Inc (NASDAQ:ALIM) by 158.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 477,226 shares of the biopharmaceutical company’s stock after acquiring an additional 292,399 shares during the quarter. Alimera Sciences comprises approximately 0.4% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned approximately 0.69% of Alimera Sciences worth $644,000 as of its most recent SEC filing. 46.11% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece was reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3301976/alimera-sciences-alim-cut-to-hold-at-zacks-investment-research.html.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Energous  Upgraded by BidaskClub to “Buy”
Energous Upgraded by BidaskClub to “Buy”
Precision Drilling  to Release Earnings on Thursday
Precision Drilling to Release Earnings on Thursday
CRISPR Therapeutics  Downgraded to “Buy” at BidaskClub
CRISPR Therapeutics Downgraded to “Buy” at BidaskClub
Biogen  Given New $0.00 Price Target at Piper Jaffray
Biogen Given New $0.00 Price Target at Piper Jaffray
Pioneer Natural Resources  Sets New 52-Week High and Low After Analyst Upgrade
Pioneer Natural Resources Sets New 52-Week High and Low After Analyst Upgrade
Sierra Bancorp  Given a $31.00 Price Target at Hovde Group
Sierra Bancorp Given a $31.00 Price Target at Hovde Group


© 2006-2018 Ticker Report. Google+.